Business
PDS announces proposed offering of common stock
PDS announces proposed offering of common stock.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8681B\n NetScientific PLC\n 15 June 2021\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\", the \"Group\" or the \"Company\")\n \n \n \n \n \n PDS Biotech Announces Proposed Offering of Common Stock\n \n \n \n \n \n \n London, UK - 15 June 2021\n \n - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced that it has commenced an underwritten public offering of shares of its common stock\n \n \n \n \n The full text of the announcement from PDS Biotechnology is reproduced below and is available online here: https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/536-iotechnnouncesroposedfferingofommontock20210614\n \n ###\n \n \n \n \n FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (\"PDS Biotech\" or the \"Company\"), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.\n \n \n \n \n \n Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.\n \n \n \n \n \n PDS Biotech intends to use a portion of the net proceeds from this offering for the development of our clinical pipeline and for general corporate purposes including working capital.\n \n \n \n \n \n A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the \"SEC\") and became effective on July 31, 2020. A preliminary prospectus supplement relating to the ...